ICMJE DISCLOSURE FORM

Date: 40ct2021			
Your Name: Peter Jüni			
Manuscript Title:	RAPID	 	
Manuscript number (if k	nown):		_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Dr. Jüni reports funding from Task 54, Defense Research Development Canada, Department of National Defense, Ottawa, Canada (to institution), St Michael's Hospital Foundation, Toronto, Canada (to institution), St Joseph's Health Centre Foundation, Toronto, Canada (to institution), International Network of Venous Thromboembolism Clinical Research Networks (INVENT) Kickstarter Award (to institution)
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Appili Therapeutics	Dr. Jüni reports a grant to the institution from Appili Therapeutics.

3	Royalties or licenses	None	
	·		
4	Consulting fees	Amgen and Fresenius	Dr. Jüni reports payment to the institution for participation in advisory boards and/or consulting for Amgen and Fresenius.
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Amgen, Ava, Fresenius	Dr. Jüni reports honoraria to the institution from Amgen, from Ava, from Fresenius.
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	Amgen, Ava, Fresenius	Dr. Jüni reports travel reimbursement to the institution from Amgen, from Ava, from Fresenius.
8	Patents planned, issued or	None	
0	pending	None	
	Perionis		
9	Participation on a Data Safety Monitoring Board or Advisory Board	Amgen and Fresenius	Dr. Jüni has participated in advisory boards and/or consulting for Amgen and Fresenius.
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy		
11	group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical	NONC	
writing, gifts or other services			
13	Other financial or non-	Appili Therapeutics,	Dr. Jüni serves as unpaid member of the steering group
	financial interests	Abbott Vascular, Terumo	of trials funded by Appili Therapeutics, Abbott Vascular (EXCEL trial: https://clinicaltrials.gov/ct2/show/NCT01205776; comparing XIENCE Stent in subjects with unprotected left main coronary artery disease with coronary artery bypass graft surgery; no active involvement for >3 years, no co-authored publication, but still listed as original member of statistical executive committee) and Terumo (MASTER DAPT trial: https://www.clinicaltrials.gov/ct2/show/NCT03023020;

	comparing abbreviated DAPT with prolonged DAPT in patients with a drug-eluting stent; ongoing active involvement as member of steering group).

Please place an "X" next to the following statement to indicate your agreement:

_ X __ I certify that I have answered every question and have not altered the wording of any of the questions on this form.